Long-term sirolimus in verrucous venous malformation cohort study and ponatinib as a potential therapeutic strategy for MAP3K3-mutatant-patient in vitro

Name: Long-term sirolimus in verrucous venous malformation cohort study and ponatinib as a potential therapeutic strategy for MAP3K3-mutatant-patient in vitro
Creator: jialu yu
Published: 2025-11-17T16:28:46.985Z
Keywords: Dermatology, Vascular Malformation, Ponatinib, Sirolimus

yu, jialu; Zhang, Gaolei; Chen, Hongguang; Wang, Xiuwei; Su, Mengting; Li, Qian; Wang, Yuhan; Zhang, Sheng; Liu, Xiaoyan; Wang, Jianhua

doi:10.17632/btdxd73nxj.4

Long-term sirolimus in verrucous venous malformation cohort study and ponatinib as a potential therapeutic strategy for MAP3K3-mutatant-patient in vitro

Published: 17 November 2025| Version 4 | DOI: 10.17632/btdxd73nxj.4

Contributors:

jialu yu, Gaolei Zhang, Hongguang Chen, Xiuwei Wang, Mengting Su, Qian Li, Yuhan Wang, Sheng Zhang, Xiaoyan Liu, Jianhua Wang

Description

"Long-term sirolimus in verrucous venous malformation cohort study and ponatinib as a potential therapeutic strategy for MAP3K3-mutatant-patient in vitro" Supplemental Data for JAAD Brief Report.

Long-term sirolimus in verrucous venous malformation cohort study and ponatinib as a potential therapeutic strategy for MAP3K3-mutatant-patient in vitro

Description

Files

Categories

Licence